Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.

Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S.

Cells. 2019 May 17;8(5). pii: E472. doi: 10.3390/cells8050472. Review.

2.

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.

Darowski D, Kobold S, Jost C, Klein C.

MAbs. 2019 May/Jun;11(4):621-631. doi: 10.1080/19420862.2019.1596511. Epub 2019 Apr 17.

PMID:
30892136
3.

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S.

Int J Mol Sci. 2019 Mar 14;20(6). pii: E1283. doi: 10.3390/ijms20061283. Review.

4.

Innate Immune Stimulation in Cancer Therapy.

Düwell P, Heidegger S, Kobold S.

Hematol Oncol Clin North Am. 2019 Apr;33(2):215-231. doi: 10.1016/j.hoc.2018.12.002. Epub 2019 Jan 9. Review.

PMID:
30832996
5.

Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology.

Libby P, Kobold S.

Cardiovasc Res. 2019 Apr 15;115(5):824-829. doi: 10.1093/cvr/cvz058.

PMID:
30830168
6.

Enhancing tumor T cell infiltration to enable cancer immunotherapy.

Zhang J, Endres S, Kobold S.

Immunotherapy. 2019 Feb;11(3):201-213. doi: 10.2217/imt-2018-0111.

PMID:
30730277
7.

Innate and adaptive immunity combined for cancer treatment.

Kobold S.

Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1087-1088. doi: 10.1073/pnas.1820166116. Epub 2018 Dec 17. No abstract available.

PMID:
30559210
8.

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma.

Wiedemann GM, Aithal C, Kraechan A, Heise C, Cadilha BL, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.

Transl Oncol. 2019 Feb;12(2):350-360. doi: 10.1016/j.tranon.2018.10.014. Epub 2018 Nov 28.

9.

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.

Rataj F, Jacobi SJ, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha BL, van Puijenbroek E, Heise C, Duewell P, Endres S, Klein C, Kobold S.

Br J Cancer. 2019 Jan;120(1):79-87. doi: 10.1038/s41416-018-0341-1. Epub 2018 Nov 15.

PMID:
30429531
10.

Teaching an old dog new tricks: next-generation CAR T cells.

Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S.

Br J Cancer. 2019 Jan;120(1):26-37. doi: 10.1038/s41416-018-0325-1. Epub 2018 Nov 9.

PMID:
30413825
11.

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.

Blood. 2018 Dec 6;132(23):2484-2494. doi: 10.1182/blood-2018-05-849802. Epub 2018 Oct 1.

PMID:
30275109
12.

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.

Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S.

Front Immunol. 2018 Aug 30;9:1955. doi: 10.3389/fimmu.2018.01955. eCollection 2018.

13.

IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis.

Weidenbusch M, Song S, Iwakura T, Shi C, Rodler S, Kobold S, Mulay SR, Honarpisheh MM, Anders HJ.

Physiol Rep. 2018 Aug;6(16):e13817. doi: 10.14814/phy2.13817.

14.

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.

Kobold S, Pantelyushin S, Rataj F, Vom Berg J.

Front Oncol. 2018 Jul 25;8:285. doi: 10.3389/fonc.2018.00285. eCollection 2018. Review.

15.

Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials.

Guhr A, Kobold S, Seltmann S, Seiler Wulczyn AEM, Kurtz A, Löser P.

Stem Cell Reports. 2018 Aug 14;11(2):485-496. doi: 10.1016/j.stemcr.2018.06.012. Epub 2018 Jul 19.

16.

[Immuno-Oncology: A Brief Overview].

Kobold S, Krackhardt A, Schlösser H, Wolf D.

Dtsch Med Wochenschr. 2018 Jul;143(14):1006-1013. doi: 10.1055/a-0623-9147. Epub 2018 Jul 13. Review. German.

PMID:
30005434
17.

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.

Metzger P, Kirchleitner SV, Koenig LM, Hörth C, Kobold S, Endres S, Schnurr M, Duewell P.

Sci Rep. 2018 Jun 11;8(1):8810. doi: 10.1038/s41598-018-27125-6.

18.

Can we use interleukin-1β blockade for lung cancer treatment?

Gottschlich A, Endres S, Kobold S.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S160-S164. doi: 10.21037/tlcr.2018.03.15. No abstract available.

19.

Targeting interleukin-22 for cancer therapy.

Markota A, Endres S, Kobold S.

Hum Vaccin Immunother. 2018;14(8):2012-2015. doi: 10.1080/21645515.2018.1461300. Epub 2018 May 17.

20.

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi FS, Dranoff G, Wucherpfennig KW.

Science. 2018 Mar 30;359(6383):1537-1542. doi: 10.1126/science.aao0505.

PMID:
29599246
21.

Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut.

Mak'Anyengo R, Duewell P, Reichl C, Hörth C, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer C.

JCI Insight. 2018 Mar 8;3(5). pii: 96322. doi: 10.1172/jci.insight.96322.

22.

Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.

Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt KAM, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S, Kobold S.

Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12994-12999. doi: 10.1073/pnas.1705165114. Epub 2017 Nov 17.

23.

Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.

Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.

Cancer Immunol Res. 2017 Sep;5(9):730-743. doi: 10.1158/2326-6066.CIR-16-0236. Epub 2017 Aug 4.

24.

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.

Oncoimmunology. 2016 May 31;5(7):e1189051. doi: 10.1080/2162402X.2016.1189051. eCollection 2016 Jul.

25.

TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.

Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert NJ, Croasdale R, Scheuer W, Auer J, Klein C, Niederfellner G, Kobold S, Sustmann C.

Protein Eng Des Sel. 2016 Oct;29(10):467-475. doi: 10.1093/protein/gzw037. Epub 2016 Aug 29.

26.

Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.

Tufman A, Huber RM, Völk S, Aigner F, Edelmann M, Gamarra F, Kiefl R, Kahnert K, Tian F, Boulesteix AL, Endres S, Kobold S.

BMC Cancer. 2016 Jul 7;16:409. doi: 10.1186/s12885-016-2471-2.

27.

Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45.

Pritsch M, Ben-Khaled N, Chaloupka M, Kobold S, Berens-Riha N, Peter A, Liegl G, Schubert S, Hoelscher M, Löscher T, Wieser A.

J Immunol Res. 2016;2016:3576028. doi: 10.1155/2016/3576028. Epub 2016 Apr 27.

28.

C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.

Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.

Oncoimmunology. 2015 Oct 29;5(3):e1105428. eCollection 2016 Mar.

29.

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.

Roskopf CC, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.

Oncotarget. 2016 Apr 19;7(16):22579-89. doi: 10.18632/oncotarget.8022.

30.

Immunotherapy in Tumors.

Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.

Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Review.

31.

Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.

Duewell P, Beller E, Kirchleitner SV, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M.

Oncoimmunology. 2015 Apr 14;4(10):e1029698. eCollection 2015 Oct.

32.

Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.

Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger JC, Schnurr M, Endres S, Rothenfußer S.

J Natl Cancer Inst. 2015 Jun 23;107(8). pii: djv146. doi: 10.1093/jnci/djv146. Print 2015 Aug.

33.

Strategies to relieve immunosuppression in pancreatic cancer.

Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S.

Immunotherapy. 2015;7(4):363-76. doi: 10.2217/imt.15.9. Review.

PMID:
25917628
34.

Human embryonic and induced pluripotent stem cell research trends: complementation and diversification of the field.

Kobold S, Guhr A, Kurtz A, Löser P.

Stem Cell Reports. 2015 May 12;4(5):914-25. doi: 10.1016/j.stemcr.2015.03.002. Epub 2015 Apr 9.

35.

Modes of action of TLR7 agonists in cancer therapy.

Kobold S, Wiedemann G, Rothenfußer S, Endres S.

Immunotherapy. 2014;6(10):1085-95. doi: 10.2217/imt.14.75. Review.

PMID:
25428647
36.

Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.

Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.

J Natl Cancer Inst. 2014 Nov 24;107(1):364. doi: 10.1093/jnci/dju364. Print 2015 Jan.

PMID:
25424197
37.

T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.

Roskopf CC, Schiller CB, Braciak TA, Kobold S, Schubert IA, Fey GH, Hopfner KP, Oduncu FS.

Oncotarget. 2014 Aug 15;5(15):6466-83.

38.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.

Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.

Cancer Immunol Immunother. 2014 Nov;63(11):1151-62. doi: 10.1007/s00262-014-1588-x. Epub 2014 Jul 31.

PMID:
25078248
39.

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.

Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, Endres S, Schnurr M.

Cell Death Differ. 2014 Dec;21(12):1825-37. doi: 10.1038/cdd.2014.96. Epub 2014 Jul 11. Erratum in: Cell Death Differ. 2014 Dec;21(12):161.

40.

Toll-like receptor 4-induced IL-22 accelerates kidney regeneration.

Kulkarni OP, Hartter I, Mulay SR, Hagemann J, Darisipudi MN, Kumar Vr S, Romoli S, Thomasova D, Ryu M, Kobold S, Anders HJ.

J Am Soc Nephrol. 2014 May;25(5):978-89. doi: 10.1681/ASN.2013050528. Epub 2014 Jan 23.

41.
42.

Virus-associated activation of innate immunity induces rapid disruption of Peyer's patches in mice.

Heidegger S, Anz D, Stephan N, Bohn B, Herbst T, Fendler WP, Suhartha N, Sandholzer N, Kobold S, Hotz C, Eisenächer K, Radtke-Schuller S, Endres S, Bourquin C.

Blood. 2013 Oct 10;122(15):2591-9. doi: 10.1182/blood-2013-01-479311. Epub 2013 Jul 3.

43.

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.

Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C.

Oncogene. 2013 Dec 12;32(50):5593-601. doi: 10.1038/onc.2013.245. Epub 2013 Jul 1.

44.

Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells.

Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A, Düwell P, Lindner M, Koch I, Heidegger S, Rothenfuer S, Schnurr M, Huber RM, Wilczak W, Endres S.

J Thorac Oncol. 2013 Aug;8(8):1032-42. doi: 10.1097/JTO.0b013e31829923c8.

45.

Power-laws and the use of pluripotent stem cell lines.

Schuldt BM, Guhr A, Lenz M, Kobold S, MacArthur BD, Schuppert A, Löser P, Müller FJ.

PLoS One. 2013;8(1):e52068. doi: 10.1371/journal.pone.0052068. Epub 2013 Jan 2.

46.

Scope and impact of international research in human pluripotent stem cells.

Löser P, Kobold S, Guhr A, Müller FJ, Kurtz A.

Stem Cell Rev. 2012 Dec;8(4):1048-55. doi: 10.1007/s12015-012-9409-0.

47.

Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.

Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D.

Clin Dev Immunol. 2012;2012:134081. doi: 10.1155/2012/134081. Epub 2012 Mar 12.

48.

Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.

Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.

Clin Dev Immunol. 2011;2011:302145. doi: 10.1155/2011/302145. Epub 2011 Nov 15.

49.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.

Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander AR, Marx AH, Bokemeyer C, Kröger N.

Haematologica. 2011 Oct;96(10):1512-20. doi: 10.3324/haematol.2010.036814. Epub 2011 May 23.

50.

Prognostic and diagnostic value of spontaneous tumor-related antibodies.

Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D.

Clin Dev Immunol. 2010;2010:721531. doi: 10.1155/2010/721531. Epub 2010 Dec 23. Review.

Supplemental Content

Loading ...
Support Center